[go: up one dir, main page]

DE69229640D1 - Teilchen, methode zur herstellung der teilchen und deren verwendung - Google Patents

Teilchen, methode zur herstellung der teilchen und deren verwendung

Info

Publication number
DE69229640D1
DE69229640D1 DE69229640T DE69229640T DE69229640D1 DE 69229640 D1 DE69229640 D1 DE 69229640D1 DE 69229640 T DE69229640 T DE 69229640T DE 69229640 T DE69229640 T DE 69229640T DE 69229640 D1 DE69229640 D1 DE 69229640D1
Authority
DE
Germany
Prior art keywords
phase
particles
pct
homogeneous
date apr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69229640T
Other languages
English (en)
Other versions
DE69229640T2 (de
Inventor
Tomas Landh
Kare Larssons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandberg Development AB
Original Assignee
GS Development AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GS Development AB filed Critical GS Development AB
Priority claimed from PCT/SE1992/000692 external-priority patent/WO1993006921A1/en
Publication of DE69229640D1 publication Critical patent/DE69229640D1/de
Application granted granted Critical
Publication of DE69229640T2 publication Critical patent/DE69229640T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02Making microcapsules or microballoons
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00Liquid crystal materials
    • C09K19/02Liquid crystal materials characterised by optical, electrical or physical properties of the components, in general
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00Liquid crystal materials
    • C09K19/52Liquid crystal materials characterised by components which are not liquid crystals, e.g. additives with special physical aspect: solvents, solid particles
    • C09K19/54Additives having no specific mesophase characterised by their chemical composition
    • C09K19/542Macromolecular compounds
    • C09K19/544Macromolecular compounds as dispersing or encapsulating medium around the liquid crystal
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00Liquid crystal materials
    • C09K19/52Liquid crystal materials characterised by components which are not liquid crystals, e.g. additives with special physical aspect: solvents, solid particles
    • C09K2019/528Surfactants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S516/00Colloid systems and wetting agents; subcombinations thereof; processes of
    • Y10S516/90Liquid crystal material of, or for, colloid system, e.g. g phase
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Colloid Chemistry (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE69229640T 1991-10-04 1992-10-02 Teilchen, methode zur herstellung der teilchen und deren verwendung Expired - Lifetime DE69229640T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77101491A 1991-10-04 1991-10-04
PCT/SE1992/000692 WO1993006921A1 (en) 1991-10-04 1992-10-02 Particles, method of preparing said particles and uses thereof

Publications (2)

Publication Number Publication Date
DE69229640D1 true DE69229640D1 (de) 1999-08-26
DE69229640T2 DE69229640T2 (de) 1999-12-16

Family

ID=25090424

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69229640T Expired - Lifetime DE69229640T2 (de) 1991-10-04 1992-10-02 Teilchen, methode zur herstellung der teilchen und deren verwendung

Country Status (10)

Country Link
US (1) US5531925A (de)
EP (1) EP0643620B1 (de)
JP (1) JP3571717B2 (de)
AT (1) ATE182278T1 (de)
AU (1) AU2699892A (de)
BR (1) BR9206593A (de)
CA (1) CA2120359C (de)
DE (1) DE69229640T2 (de)
ES (1) ES2133391T3 (de)
FI (1) FI941538A7 (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2085827C (en) * 1991-12-23 2003-10-14 Lucas A. T. Hilgers Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
US6277410B1 (en) 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
FR2726762B1 (fr) * 1994-11-10 1997-01-17 Oreal Composition cosmetique ou dermatologique sous forme d'une dispersion d'une phase huileuse dans une phase aqueuse stabilisee a l'aide de particules de gel cubique et son procede d'obtention
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US6359054B1 (en) 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US6040295A (en) * 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
JPH08254688A (ja) * 1995-03-16 1996-10-01 Toshiba Corp 液晶表示素子
US6248720B1 (en) * 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
JPH11510142A (ja) 1995-07-21 1999-09-07 ブラウン・ユニバーシティ・リサーチ・ファンデーション 核酸負荷ポリマー微粒子を使用した遺伝子治療法
JP2000500744A (ja) * 1995-11-09 2000-01-25 マイクロバイオロジカル リサーチ オーソリティー ワクチン接種および遺伝子治療のためのマイクロカプセル化dna
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
US6284375B1 (en) * 1996-10-18 2001-09-04 Tuo Jin Lipid vesicle system
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
US6106609A (en) * 1997-04-08 2000-08-22 The United States Of America As Represented By The Secretary Of The Navy Formation of nanocrystalline semiconductor particles within a bicontinuous cubic phase
US5962015A (en) * 1997-05-02 1999-10-05 Kobo Products S.A.R.L. Stabilized liposomes
EP0875232B1 (de) * 1997-05-02 2002-02-13 Takasago International Corporation Flüssigkristallphase enthaltende Lipidzusammensetzung
US6638621B2 (en) * 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
CN1138591C (zh) * 1997-09-09 2004-02-18 莱奥特罗皮克治疗公司 包覆颗粒以及其制备和使用方法
SE9703458D0 (sv) * 1997-09-25 1997-09-25 Pharmacia & Upjohn Ab Nicotine compositions and methods of formulation thereof
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
CA2335460A1 (en) 1998-06-18 1999-12-23 Johns Hopkins University School Of Medicine Polymers for delivery of nucleic acids
US6916490B1 (en) 1998-07-23 2005-07-12 UAB Research Center Controlled release of bioactive substances
CA2342832A1 (en) * 1998-09-04 2000-03-16 Powderject Research Limited Immunodiagnostics using particle delivery methods
ES2231263T3 (es) * 1999-08-06 2005-05-16 Max-Delbruck-Centrum Fur Molekulare Medizin Sistemas de liberizacion sostenida de principio activo implantable.
US20050037086A1 (en) * 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
KR20010100194A (ko) * 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
JP2003535122A (ja) * 2000-06-02 2003-11-25 ザイコス インク. 生物活性物質のための送達システム
US20020153508A1 (en) * 2000-06-29 2002-10-24 Lynch Matthew Lawrence Cubic liquid crystalline compositions and methods for their preparation
US20040266983A1 (en) * 2000-08-17 2004-12-30 Reeve Lorraine E Purified polyoxyalkylene block copolymers
DE10057770A1 (de) * 2000-11-22 2002-05-23 Beiersdorf Ag Hautpflegeprodukte mit einem Gehalt an dispersen Flüssigkristallen, welche kubische Phasen darstellen ,
DE60129156T2 (de) * 2000-11-29 2008-03-13 Lyotropic Therapeutics, Inc. Lösungsmittelsysteme für pharmazeutische mittel
US7008646B2 (en) 2001-02-20 2006-03-07 Patrick Thomas Spicer Cubic liquid crystalline compositions and methods for their preparation
US6656385B2 (en) * 2001-02-21 2003-12-02 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6936187B2 (en) 2001-02-21 2005-08-30 Matthew Lawrence Lynch Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US20030060695A1 (en) * 2001-03-07 2003-03-27 Connelly Patrick R. Implantable artificial organ devices
US6991809B2 (en) * 2001-06-23 2006-01-31 Lyotropic Therapeutics, Inc. Particles with improved solubilization capacity
GB0118300D0 (en) * 2001-07-26 2001-09-19 Cortendo Ab Formulations
CA2456806C (en) * 2001-08-08 2011-10-18 Brown University Research Foundation Methods for micronization of hydrophobic drugs
US20040022820A1 (en) * 2001-11-28 2004-02-05 David Anderson Reversed liquid crystalline phases with non-paraffin hydrophobes
AU2002360549A1 (en) * 2001-12-10 2003-06-23 Spherics, Inc. Methods and products useful in the formation and isolation of microparticles
WO2003090693A2 (en) * 2002-04-23 2003-11-06 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing lamotrigine particles of defined morphology
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
US20030232340A1 (en) * 2002-06-13 2003-12-18 David Anderson Nanoporous particle with a retained target
JP2005529949A (ja) * 2002-06-13 2005-10-06 リオトロピック セラピュティックス アイエヌシー. 被覆粒子、製造方法および使用
US20040156816A1 (en) * 2002-08-06 2004-08-12 David Anderson Lipid-drug complexes in reversed liquid and liquid crystalline phases
GB0305941D0 (en) * 2003-03-14 2003-04-23 Camurus Ab Composition
US20050119340A1 (en) * 2003-06-13 2005-06-02 David Anderson Treatment methods with low-dose, longer-acting formulations of local anesthetics and other agents
JP2007501213A (ja) * 2003-08-04 2007-01-25 カムルス エービー 両親媒性粒子に活性因子を装填する方法
CA2546482A1 (en) * 2003-09-01 2005-03-10 F H Faulding & Co Limited Compositions and methods for delivery of biologically active agents
GB0322033D0 (en) * 2003-09-19 2003-10-22 Camurus Ab Composition
PT1663321E (pt) 2003-09-22 2012-11-15 Baxter Int Esterilização a alta pressão para esterilizar definitivamente preparações farmacêuticas e produtos médicos
US20070293441A1 (en) * 2003-09-22 2007-12-20 Baxter International Inc. High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products
US7713440B2 (en) * 2003-10-08 2010-05-11 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
AU2005324794C1 (en) * 2003-11-07 2010-12-02 Camurus Ab Somatostatin analogue formulations
DK1682091T3 (en) * 2003-11-07 2017-05-15 Camurus Ab COMPOSITIONS OF LIPIDS AND CATIONIC PEPTIDES
GB0401513D0 (en) * 2004-01-23 2004-02-25 Camurus Ab Compositions
JP4966018B2 (ja) 2004-01-23 2012-07-04 カムルス エービー 三元非ラメラ脂質組成物
EP1598060A1 (de) * 2004-05-18 2005-11-23 Nestec S.A. Öl-in-Wasser-Emulsion für Lieferung
GB0417388D0 (en) * 2004-08-04 2004-09-08 Camurus Ab Composition
CA2575906C (en) * 2004-08-04 2014-04-15 Camurus Ab Compositions forming non-lamellar dispersions
US8535709B2 (en) * 2004-12-13 2013-09-17 Southeastern Medical Technologies, Llc Agents for controlling biological fluids and methods of use thereof
US20060127437A1 (en) * 2004-12-13 2006-06-15 Misty Anderson Kennedy Semisolid system and combination semisolid, multiparticulate system for sealing tissues and/or controlling biological fluids
US20070059350A1 (en) * 2004-12-13 2007-03-15 Kennedy John P Agents for controlling biological fluids and methods of use thereof
US8871712B2 (en) * 2005-01-14 2014-10-28 Camurus Ab Somatostatin analogue formulations
ES2458992T3 (es) 2005-01-14 2014-05-07 Camurus Ab Formulaciones de análogos de GnRH
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
GB0501364D0 (en) * 2005-01-21 2005-03-02 Camurus Ab Compositions
CA2595385C (en) * 2005-01-21 2011-01-25 Camurus Ab Pharmaceutical lipid compositions
US7125954B2 (en) 2005-01-27 2006-10-24 General Electric Company Method for producing polyether polymers
US8546326B2 (en) * 2005-06-06 2013-10-01 Camurus Ab Glp-1 analogue formulations
RU2318947C2 (ru) * 2006-02-28 2008-03-10 Московский автомобильно-дорожный институт (Государственный технический университет) Способ устройства дорожного покрытия
WO2008034082A2 (en) * 2006-09-15 2008-03-20 Maroon Biotech, Corporation Method of using amphiphilic multiblock copolymers in food
CZ2006697A3 (cs) * 2006-11-07 2008-05-21 Zentiva, A. S. Kompozice depotních olanzapinových injekcních systému
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
JP2008120838A (ja) * 2008-02-21 2008-05-29 Medgel Corp 配位結合を利用した薬物−高分子複合体製剤の調製方法
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
EP2393472B1 (de) * 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
EP2422186A1 (de) * 2009-04-22 2012-02-29 Wisconsin Alumni Research Foundation Analytnachweis unter verwendung von flüssigkristallen
US9668974B2 (en) * 2012-05-10 2017-06-06 Painreform Ltd. Depot formulations of a local anesthetic and methods for preparation thereof
KR102139080B1 (ko) 2012-05-25 2020-07-29 카무러스 에이비 소마토스타틴 수용체 작용제 제형
HRP20200372T1 (hr) 2014-03-25 2020-06-12 F. Hoffmann - La Roche Ag Postupci proizvodnje poloksamera za upotrebu u mediju za staničnu kulturu
CN107205956A (zh) 2014-10-30 2017-09-26 纺织品技术股份有限公司 输送系统
EP3784681A4 (de) 2018-04-26 2022-10-26 NanoMed Holdings Pty Ltd Gemcitabin-amphiphil-prodrugs
WO2019241853A1 (en) 2018-06-21 2019-12-26 NanoMed Holdings Pty Ltd Platinum-based amphiphile prodrugs
US12332254B2 (en) 2019-04-24 2025-06-17 Cornell University Systems, compositions, and methods for evaluating biomechanical properties of cells
US20230057782A1 (en) * 2020-02-03 2023-02-23 Curemast, Inc. Compositions and methods of use thereof for treatment of mastitis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8206744D0 (sv) * 1982-11-26 1982-11-26 Fluidcarbon International Ab Preparat for kontrollerad avgivning av substanser
US4556289A (en) * 1983-03-21 1985-12-03 Manchester R & D Partnership Low birefringence encapsulated liquid crystal and optical shutter using same
US5371109A (en) * 1986-07-01 1994-12-06 Drilletten Ab Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
GB8803037D0 (en) * 1988-02-10 1988-03-09 Unilever Plc Aqueous detergent compositions & methods of forming them
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5108756A (en) * 1989-01-12 1992-04-28 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5143934A (en) * 1990-11-21 1992-09-01 A/S Dumex (Dumex Ltd.) Method and composition for controlled delivery of biologically active agents
JPH03139525A (ja) * 1989-10-24 1991-06-13 Sunstar Eng Inc 紫外線硬化性組成物

Also Published As

Publication number Publication date
JP3571717B2 (ja) 2004-09-29
ES2133391T3 (es) 1999-09-16
JPH07502197A (ja) 1995-03-09
CA2120359A1 (en) 1993-04-15
EP0643620A1 (de) 1995-03-22
FI941538L (fi) 1994-05-31
US5531925A (en) 1996-07-02
FI941538A0 (fi) 1994-03-31
BR9206593A (pt) 1995-11-28
CA2120359C (en) 2000-12-26
EP0643620B1 (de) 1999-07-21
ATE182278T1 (de) 1999-08-15
FI941538A7 (fi) 1994-05-31
DE69229640T2 (de) 1999-12-16
AU2699892A (en) 1993-05-03

Similar Documents

Publication Publication Date Title
ATE182278T1 (de) Teilchen, methode zur herstellung der teilchen und deren verwendung
NO941191L (no) Partikler, fremgangsmåte for fremstilling samt anvendelse av slike
RU2159761C2 (ru) Замещенные 4-биарилмасляные или 5-биарилпентановые кислоты или их производные, способы их получения, фармацевтическая композиция и способ лечения
AU3506893A (en) Use of fullerenes in diagnostic and/or therapeutic agents
DE69333607D1 (de) Vorrichtung zur Herstellung von vorgefüllten, sterilen Abgabevorrichtungen
IL109448A0 (en) Risperidone pamoate, its preparation and pharmaceutical compositions containing it
AU5653994A (en) Application of carbamazepine and oxcarbazepine in the treatment of neurological lesions related to traumatic injuries
FR05C0045I1 (de)
PL307914A1 (en) Lipopetide derivatives, method of obtaining them and therapeutic agents containing such compounds
AU6194286A (en) New carboxylic acid derivatives, their manufacturing process,use and medicines containing these compounds
DE69504509D1 (de) Thiazolidinderivate, ihre herstellung und medikamente, die sie enthalten
EP0137440A3 (de) Cephalosporinderivate und Verfahren zu ihrer Herstellung
EP0137441A3 (de) Cephalosporinderivate und Verfahren zu ihrer Herstellung
ATE59757T1 (de) Phospholipidhaltige produkte, deren herstellung und verwendung.
ATE69138T1 (de) Pestizide biosynthetische produkte enthaltende zusammensetzungen, verfahren zu ihrer herstellung und ihre verwendung.
EP0329008A3 (de) Cephalosporinderivative und Verfahren zu ihrer Herstellung
GR3026324T3 (en) Use of prostacyclin derivatives to prevent or treat disorders of the microcirculating system when x-ray, nmr or ultrasonic contrasting agents are administered.
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
FR2725718B1 (fr) Bis-2-aminopyridines, leur procede de preparation et leurs applications
NO307933B1 (no) Vann-uløselig eller lite vannløselig terapeutisk forbindelse, anvendelse derav samt farmasøytisk blanding inneholdende nevnte forbindelse
EP0379132A3 (de) Cephalosporinderivate und Verfahren zu ihrer Herstellung
GR3008746T3 (de)
WO2000021577A3 (en) Compositions
Greenberg Give'em health, Harry.
AU674909B2 (en) New triazoloquinazolines, their production and their use

Legal Events

Date Code Title Description
R071 Expiry of right

Ref document number: 643620

Country of ref document: EP